Press releases
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
- Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
- Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.04 |
---|---|
High | 47.04 |
Low | 47.04 |
Bid | 46.98 |
Offer | 47.13 |
Previous close | 42.51 |
Average volume | 68.20 |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 18.32 |
Market cap | 5.64bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:11 BST.
More ▼